Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure

No abstract is available for this paper.

• Publication year

  1981

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  1981-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00561947PMID 7215416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia.

  2009cited by this paper
• Disopyramide plasma levels in cardiac patients on maintenance therapy.

  2009cited by this paper
• Quinidine concentration in blood and excretion in urine following parenteral administration as related to congestive heart failure.

  2009cited by this paper
• Arrhythmia prophylaxis with procaine amide: plasma concentrations in relation to dose.

  2009cited by this paper
• Gas-chromatographic determination of disopyramide and its mono-N-dealkylated metabolite in serum with use of a nitrogen-selective detector.

  1980cited by this paper
• Disopyramide.

  1979cited by this paper
• Drug therapy: bretylium.

  1979cited by this paper
• Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

  1978influential reference
• The effect of non-linear disposition kinetics on the systemic availability of disopyramide

  1978cited by this paper
• Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration.

  1977cited by this paper
• The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.

  1977cited by this paper
• Effects of disopyramide on electrophysiologic properties of canine cardiac purkinje fibers.

  1977cited by this paper
• A Comparison of the Dissolution and Bioavailability Characteristics of Three Spironolactone Tablet Formulations, Including Preliminary Data on Two Spironolactone Metabolites

  1976cited by this paper
• Pharmacokinetics in Patients with Cardiac Failure

  1976cited by this paper
• The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.

  1976cited by this paper
• Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.

  1976cited by this paper
• Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: Correlation of the kinetics of the drug and its effects

  1976cited by this paper
• The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.

  1976cited by this paper
• Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans

  1976cited by this paper
• Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.

  1976cited by this paper
• Acute termination of cardiac arrhythmias with intravenous disopyramide.

  1976cited by this paper
• Anafranil in the management of long-term pain: a preliminary report.

  1976cited by this paper
• Acute termination of cardiac arrhythmias with intravenous disopyramide.

  1976cited by this paper
• The use of disopyramide in the treatment of arrhythmias in ambulatory patients.

  1976cited by this paper
• The pharmacokinetics of Norpace.

  1975cited by this paper
• The effect of congestive heart failure on quinidine pharmacokinetics.

  1975cited by this paper
• Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins.

  1974cited by this paper
• Effects of verapamil on electrophysiologic properties of canine cardiac Purkinje fibers.

  1974cited by this paper
• Pharmacokinetic of procainamide in man.

  1971cited by this paper
• PHARMACOKINETICS OF PROCAINAMIDE IN MAN *

  1971cited by this paper
• Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency.

  1971cited by this paper
• Blood Levels of Drug at the Equilibrium State after Multiple Dosing

  1965cited by this paper
• The uptake of thiopental by body tissues and its relation to the duration of narcosis

  1960cited by this paper

• Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.

  2009cites this paper
• Written consent to use the drug in children: the problem of off-label drugs.

  2008cites this paper
• Practical pharmacokinetics of ventricular antiarrhythmic therapy.

  1992cites this paper
• Pharmakologie der Antiarrhythmika

  1991cites this paper
• Practical Optimisation of Antiarrhythmic Drug Therapy Using Pharmacokinetic Principles

  1991cites this paper
• Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

  1990cites this paper
• Effects of cardiovascular disease on pharmacokinetics

  1989cites this paper
• Clinical pharmacokinetics in heart failure. An updated review.

  1988cites this paper
• Disopyramide pharmacokinetics in the elderly after single oral administration.

  1988cites this paper
• Long-term use of controlled-release disopyramide in patients with severe ventricular arrhythmias.

  1987cites this paper
• Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure.

  1987cites this paper
• Effect of Congestive Heart Failure on the Pharmacokinetics of Cibenzoline

  1987cites this paper
• Pharmacologic evaluation of standard and controlled-release disopyramide.

  1987cites this paper
• Clinical Pharmacokinetics of Disopyramide

  1986cites this paper
• Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.

  1986cites this paper
• Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and14C-disopyramide

  1984cites this paper
• Serum Drug Concentrations and Adverse Effects in Cardiac Patients After Administration of a New Controlled‐Release Disopyramide Preparation

  1984cites this paper
• 3 PHARMACOKINETICS OF ANTI-ARRHYTllllIC AGENTS IN ACUTE

  1984cites this paper
• [Problems of drug dosage in patients with cardiac insufficiency].

  1984cites this paper
• Unchanged absorption of digoxin tablets in patients with cardiac failure.

  1984cites this paper
• Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.

  1983cites this paper
• Disopyramide kinetics in renal impairment: Determinants of interindividual variability

  1983cites this paper
• Disopyramide Plasma Concentrations Following Single and Multiple Doses of the Immediate- and Controlled-Release Capsules

  1983cites this paper
• Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.

  1983cites this paper
• ORAL DISOPYRAMIDE DOSAGE REGIMES IN ISCHAEMIC HEART DISEASE

  1982cites this paper
• Clinical pharmacokinetics of disopyramide

  1982cites this paper
• Therapeutic Drug Monitoring of Antiarrhythmic Agents

  1982cites this paper
• Disopyramide pharmacokinetics during recovery from myocardial infarction.

  1982cites this paper